Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Clobetasol Propionate and Prednisolone Acetate for Treating Eye Inflammation After Cataract Surgery in Children Aged 0-3 Years

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of inflammation and pain that can occur after cataract surgery in young children aged 0 to 3 years. The study compares two different eye drop treatments: Clobetasol propionate ophthalmic nanoemulsion, 0.05% and Prednisolone acetate ophthalmic suspension, 1%. The purpose of the study is to assess the safety of these treatments in managing inflammation after surgery.

Participants in the study will receive one of the two treatments after their cataract surgery. The study will monitor the children over a period of several weeks to observe any changes in their condition. The study will include regular check-ups to assess the level of inflammation in the eye and to ensure the safety of the treatments. The study aims to determine which treatment is more effective in reducing inflammation and pain following the surgery.

Throughout the study, the children will be closely observed for any side effects or changes in their eye condition. The study will also track any changes in the pressure inside the eye and overall eye health. The results will help doctors understand which treatment is safer and more effective for young children who have undergone cataract surgery.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit and consent

    The patient, aged 0 to 3 years, is enrolled in the study after undergoing routine cataract surgery in one eye. The caregiver provides signed informed consent.

    The patient must show clinical evidence of postoperative inflammation in the eye.

  2. Step 2

    Randomization and treatment initiation

    The patient is randomly assigned to receive either Clobetasol propionate ophthalmic nanoemulsion, 0.05%, or Prednisolone acetate ophthalmic suspension, 1%.

    Both medications are administered as eye drops. The specific dosage and frequency are determined by the study protocol.

  3. Step 3

    Follow-up visit 1

    Visit 1 occurs on Day 1, where the patient's eye condition is assessed, including inflammation grade and intraocular pressure.

    The caregiver is instructed to continue administering the assigned eye drops as per the study protocol.

  4. Step 4

    Follow-up visit 2

    Visit 2 is scheduled for Day 8, with a possible variation of plus or minus 2 days.

    The patient's eye is examined for changes in inflammation and other parameters. The caregiver continues the treatment as instructed.

  5. Step 5

    Follow-up visit 3

    Visit 3 takes place on Day 15, with a possible variation of plus or minus 2 days.

    The patient's progress is monitored, focusing on inflammation and any adverse effects. Treatment continues as per the protocol.

  6. Step 6

    Follow-up visit 4

    Visit 4 is conducted on Day 29, with a possible variation of plus or minus 2 days.

    The study team evaluates the patient's response to the treatment, including inflammation levels and any side effects.

  7. Step 7

    Final follow-up visit

    Visit 5 occurs on Day 43, with a possible variation of plus or minus 3 days.

    The final assessment includes a comprehensive evaluation of the patient's eye condition, focusing on inflammation and overall eye health.

Who can join the trial?

6 criteria

  • The child must be a boy or girl aged 0 to 3 years old, meaning they have not yet turned 4 years old.
  • The child should be a candidate for routine, uncomplicated cataract surgery in one eye. This surgery may or may not include placing a lens inside the eye.
  • The child's caregiver(s) must be able and willing to follow all treatment and follow-up procedures.
  • The parents or legally authorized representative(s) of the child must sign an informed consent form, which is a document that explains the study and confirms their agreement to participate.
  • The child must have already undergone routine, uncomplicated cataract surgery in one eye, with or without a lens placed inside the eye.
  • The child must show clinical signs of inflammation after surgery. This means there is noticeable swelling or irritation inside the front part of the eye.

Who cannot join the trial?

7 criteria

  • Patients who have any other eye conditions that could affect the study results.
  • Patients who have had any other eye surgery recently.
  • Patients who are allergic to any of the study medications.
  • Patients who are taking other medications that might interfere with the study.
  • Patients who have any serious health conditions that could affect their participation.
  • Patients who are unable to follow the study instructions.
  • Patients who are participating in another clinical trial at the same time.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Clobetasol propionate

    is being tested in this trial as an eye drop in the form of a nanoemulsion. It is used to reduce inflammation after cataract surgery in young children aged 0 to 3 years. The goal is to see if it is safe and effective for this purpose.

  • Prednisolone acetate

    is another eye drop used in this trial. It is a suspension that helps reduce inflammation after cataract surgery. It is being compared to Clobetasol propionate to determine which is more effective and safe for treating inflammation in young children who have had cataract surgery.

What is already known about the treatment

  • Clobetasol Propionate Ophthalmic Nanoemulsion

    This medication is administered as eye drops and is currently being evaluated in clinical trials for its safety and effectiveness in treating inflammation and pain following ocular surgery, specifically cataract surgery in children aged 0 to 3 years. It is not yet widely used in medical practice, as it is still under investigation. The main therapeutic indication is to reduce inflammation and pain associated with eye surgery. At the molecular level, Clobetasol propionate works by inhibiting the release of substances in the body that cause inflammation. It is classified as a corticosteroid, which is a type of anti-inflammatory medication.

  • Prednisolone Acetate Ophthalmic Suspension

    This medication is also administered as eye drops and is being compared to Clobetasol propionate in clinical trials for treating inflammation after cataract surgery in young children. It is a well-established medication in medical literature and is commonly used to manage inflammation and pain following eye surgery. Prednisolone acetate works by suppressing the immune response that leads to inflammation, acting as a corticosteroid. It is widely recognized for its effectiveness in reducing swelling and discomfort in the eyes.

Investigated diseases

Inflammation and pain associated with ocular surgery – This condition occurs when the eye becomes inflamed and painful following surgical procedures, such as cataract surgery. The inflammation is typically due to the body's immune response to the surgical intervention. Symptoms may include redness, swelling, and discomfort in the eye. The condition can affect vision temporarily and may cause sensitivity to light. It usually progresses as the body heals from the surgery, with symptoms gradually decreasing over time. Management of this condition often involves monitoring and addressing the inflammation to ensure proper healing.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2024-513489-20-00Protocol codeCLOBOF3-17IA03Estimated enrolment60 patientsSponsorLaboratorios Salvat S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).